Maimaitili Yimamu

Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression

M. Mao, L. Fu, Xiaoming Wang, 2013, International Journal of Hematology.